Published in Invest Radiol on May 01, 2009
Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT. Radiology (2012) 1.62
X-ray-computed tomography contrast agents. Chem Rev (2012) 1.52
Assessment and monitoring tumor vascularity with contrast-enhanced ultrasound maximum intensity persistence imaging. Invest Radiol (2011) 1.10
Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol Histopathol (2012) 0.99
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer (2013) 0.94
Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One (2013) 0.93
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat. Neoplasia (2010) 0.89
The effect of bevacizumab on colon anastomotic healing in rats. Int J Colorectal Dis (2010) 0.84
Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies. Adv Drug Deliv Rev (2016) 0.77
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant (2006) 7.13
Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med (2003) 5.17
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro (1978) 4.67
Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol (1988) 3.06
Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology (2007) 2.79
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res (2007) 2.13
Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol (1998) 1.94
Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging (2002) 1.59
Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging (2004) 1.36
Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med (1993) 1.33
Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology (1996) 1.33
Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography. Invest Radiol (2008) 1.21
Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology (2008) 1.17
MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Radiology (2007) 1.13
Pharmacodynamics of streptavidin-coated cyanoacrylate microbubbles designed for molecular ultrasound imaging. Invest Radiol (2008) 1.03
Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization. Bioconjug Chem (2006) 1.01
MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. Radiology (2001) 1.01
Comparison of iodixanol and iohexol in renal impairment. Br J Radiol (1999) 0.98
Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol (2006) 0.97
Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med (1998) 0.93
Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma. Cancer Treat Rev (2007) 0.86
Targeting angiogenesis in advanced breast cancer. BioDrugs (2007) 0.86
Vascular endothelial growth factor inhibitors in colon cancer. Adv Exp Med Biol (2006) 0.84
MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol (2002) 0.83
Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. Acad Radiol (2000) 0.83
Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. Invest Radiol (2007) 0.82
Magnetic resonance imaging detects early changes in microvascular permeability in xenograft tumors after treatment with the matrix metalloprotease inhibitor Prinomastat. Technol Cancer Res Treat (2004) 0.82
Macromolecular contrast medium (feruglose) versus small molecular contrast medium (gadopentetate) enhanced magnetic resonance imaging: differentiation of benign and malignant breast lesions. Acad Radiol (2003) 0.81
Macromolecular contrast media-enhanced MRI estimates of microvascular permeability correlate with histopathologic tumor grade. Acad Radiol (1998) 0.80
Utility (or not) of Gd-DTPA-based dynamic MRI for breast cancer diagnosis and grading. Acad Radiol (2002) 0.80
Comparison between the efficacy of dimeric and monomeric non-ionic contrast media (iodixanol vs iopromide) in urography in patients with mild to moderate renal insufficiency. Br J Radiol (1998) 0.79
Initial computed tomography imaging experience using a new macromolecular iodinated contrast medium in experimental breast cancer. Invest Radiol (2005) 0.79
Liver fat: effect of hepatic iron deposition on evaluation with opposed-phase MR imaging. Radiology (2007) 2.48
A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol (2008) 2.40
CT and MR imaging of pericardial disease. Radiographics (2003) 2.19
Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2004) 1.98
Characterization of cystic pancreatic masses: relative accuracy of CT and MRI. AJR Am J Roentgenol (2007) 1.83
T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. Eur Radiol (2005) 1.69
Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT. Radiology (2012) 1.62
Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging (2002) 1.59
Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol (2008) 1.55
Radiologic mimics of cirrhosis. AJR Am J Roentgenol (2010) 1.53
Use of CT cholangiography to evaluate the biliary tract after liver transplantation: initial experience. Liver Transpl (2004) 1.50
Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques--initial experience. Radiology (2005) 1.48
Inverse planning simulated annealing for magnetic resonance imaging-based intracavitary high-dose-rate brachytherapy for cervical cancer. Brachytherapy (2008) 1.46
Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging (2004) 1.36
Cell labeling with the positive MR contrast agent Gadofluorine M. Eur Radiol (2007) 1.32
Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging. Radiology (2007) 1.29
Cardiovascular shunts: MR imaging evaluation. Radiographics (2003) 1.26
CT signs of hepatofugal portal venous flow in patients with cirrhosis. AJR Am J Roentgenol (2003) 1.24
Accuracy of plain abdominal radiographs in the detection of retained surgical needles in the peritoneal cavity. Ann Surg (2008) 1.24
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging (2007) 1.21
Fetal tracheolaryngeal airway obstruction: prenatal evaluation by sonography and MRI. Pediatr Radiol (2010) 1.19
Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. AJR Am J Roentgenol (2004) 1.17
Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology (2008) 1.17
CT and MRI of congenital anomalies of the seminal vesicles. AJR Am J Roentgenol (2007) 1.15
MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Radiology (2007) 1.13
Ultrasmall supraparamagnetic iron oxide-enhanced magnetic resonance imaging of antigen-induced arthritis: a comparative study between SHU 555 C, ferumoxtran-10, and ferumoxytol. Invest Radiol (2006) 1.12
Translational control of SCL-isoform expression in hematopoietic lineage choice. Genes Dev (2003) 1.10
Peritoneal calcification: causes and distinguishing features on CT. AJR Am J Roentgenol (2004) 1.10
CT differentiation of adenomyomatosis and gallbladder cancer. AJR Am J Roentgenol (2007) 1.09
Pulmonary embolism detection with dual-energy CT: experimental study of dual-source CT in rabbits. Radiology (2009) 1.08
Magnetic resonance imaging of massive ovarian edema in pregnancy. J Comput Assist Tomogr (2010) 1.08
Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr (2005) 1.06
Risk of injury to adjacent organs with lower-pole fluoroscopically guided percutaneous nephrostomy: evaluation with prone, supine, and multiplanar reformatted CT. J Vasc Interv Radiol (2005) 1.05
Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology (2003) 1.05
Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging (2008) 1.05
Dicentric chromosomes and gamma-H2AX foci formation in lymphocytes of human blood samples exposed to a CT scanner: a direct comparison of dose response relationships. Radiat Prot Dosimetry (2009) 1.04
Macromolecular contrast agents for MR mammography: current status. Eur Radiol (2002) 1.03
Are chest radiographs routinely necessary following thoracostomy tube removal? Pediatr Radiol (2001) 1.03
MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med Mol Imaging (2003) 1.02
Magnetic resonance macromolecular agents for monitoring tumor microvessels and angiogenesis inhibition. Invest Radiol (2006) 1.02
MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging (2004) 1.02
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. J Magn Reson Imaging (2005) 1.02
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res (2009) 1.01
Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization. Bioconjug Chem (2006) 1.01
Review of atypical pelvic masses on CT and MRI: expanding the differential diagnosis. Clin Imaging (2007) 1.01
Imaging of tumor angiogenesis: current approaches and future prospects. Curr Pharm Des (2006) 1.00
Renal cyst pseudoenhancement at multidetector CT: what are the effects of number of detectors and peak tube voltage? Radiology (2008) 0.99
Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? Clin Imaging (2009) 0.99
Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Clin Imaging (2006) 0.98
Frequency and etiology of midesophageal diverticula at barium esophagography. Clin Imaging (2006) 0.98
Quantitative whole heart stress perfusion CT imaging as noninvasive assessment of hemodynamics in coronary artery stenosis: preliminary animal experience. Invest Radiol (2010) 0.98
Photoelectric-enhanced radiation therapy with quasi-monochromatic computed tomography. Med Phys (2009) 0.96
CT radiation dose: what can you do right now in your practice? AJR Am J Roentgenol (2011) 0.96
Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. J Am Coll Cardiol (2007) 0.96
Computed tomographic distinction of perirenal liposarcoma from exophytic angiomyolipoma: a feature analysis study. J Comput Assist Tomogr (2008) 0.95
Optimizing contrast media injection protocols in state-of-the art computed tomographic angiography. Invest Radiol (2015) 0.95
Physiology of renal medullary tip hyperattenuation at unenhanced CT: urinary specific gravity and the NaCl concentration gradient. Radiology (2008) 0.95
The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. Invest Radiol (2005) 0.95
Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging (2009) 0.94
Minor morphologic abnormalities of adrenal glands at CT: prognostic importance in patients with lung cancer. Radiology (2005) 0.94
Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Invest Radiol (2017) 0.94
Computed tomography of corpus luteal cysts. J Comput Assist Tomogr (2004) 0.93
Hepatobiliary agents and their role in LI-RADS. Abdom Imaging (2015) 0.93
Dual source dual-energy computed tomography of acute myocardial infarction: correlation with histopathologic findings in a canine model. Invest Radiol (2010) 0.93
Magnetic resonance cholangiography of biliary strictures after liver transplantation: a prospective double-blind study. J Magn Reson Imaging (2007) 0.93
Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol (2007) 0.93
MRI of adnexal masses in pregnancy. AJR Am J Roentgenol (2008) 0.93
Retention of iodine and expression of biomarkers for renal damage in the kidney after application of iodinated contrast media in rats. Invest Radiol (2009) 0.92
Ureteral fibroepithelial polyp. J Ultrasound Med (2008) 0.92
In vivo differentiation of complementary contrast media at dual-energy CT. Radiology (2012) 0.92
Signal Increase on Unenhanced T1-Weighted Images in the Rat Brain After Repeated, Extended Doses of Gadolinium-Based Contrast Agents: Comparison of Linear and Macrocyclic Agents. Invest Radiol (2016) 0.92
Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice. Magn Reson Med (2009) 0.91
Concordance of second-order portal venous and biliary tract anatomies on MDCT angiography and MDCT cholangiography. AJR Am J Roentgenol (2005) 0.91
Superficial endometrial spread of squamous cell cervical carcinoma: a diagnostic challenge at magnetic resonance imaging. J Comput Assist Tomogr (2007) 0.90
CT and MRI of adnexal masses in patients with primary nonovarian malignancy. AJR Am J Roentgenol (2006) 0.90
Kinetic parameters and plasma zinc concentration correlate well with net loss and gain of zinc from men. J Nutr (2004) 0.89
The impact of the viscosity and osmolality of iodine contrast agents on renal elimination. Invest Radiol (2010) 0.89
Living donor candidates for right hepatic lobe transplantation: evaluation at CT cholangiography--initial experience. Radiology (2005) 0.89
Zinc absorption and kinetics during pregnancy and lactation in Brazilian women. Am J Clin Nutr (2005) 0.89
Magnetic resonance imaging of ovarian cancer arising in endometriomas. J Comput Assist Tomogr (2004) 0.89
A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis. Invest Radiol (2010) 0.88